CAR T-Cell Therapy

Keightley AmenMultiple Myeloma | December 3, 2021
Despite the successes of chimeric antigen receptor (CAR) T-cell therapy against hematologic malignancies, toxicities continue ...
Read More
Keightley AmenMultiple Myeloma | December 3, 2021
Chimeric antigen receptor (CAR) T-cell therapy has been very effective against a growing number of hematologic malignancies, ...
Keightley AmenMultiple Myeloma | December 3, 2021
A recent letter to Bone Marrow Transplantation describes results of a survey that aimed to capture the impact of the COVID-19 ...
Keightley AmenLung Cancer | November 11, 2021
Malignant mesothelioma is a treatment-resistant type of cancer that starts in the mesothelial lining of the pleura or the ...
Keightley AmenTreatment | November 11, 2021
An article appearing in the journal Therapeutic Advances in Infectious Disease called for research to explore the infectious ...
Keightley AmenTreatment | November 11, 2021
A recent article in the journal Biomedicines reviewed the potential of chimeric antigen receptor (CAR) T-cell therapy in ...
Keightley AmenMultiple Myeloma | November 11, 2021
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of multiple myeloma, but the disease is still ...
Keightley AmenTreatment | August 2, 2021
Chimeric antigen receptor (CAR) T-cell therapy is a promising new option for treatment of hematologic malignancies, but many ...
Keightley AmenTreatment | August 2, 2021
Chimeric antigen receptor (CAR) T-cell therapy has provided a novel, effective treatment option for patients with relapsed or ...
Keightley AmenLung Cancer | August 2, 2021
Early research did not show that chimeric antigen receptor (CAR) T-cell therapy is effective against lung cancer, a solid ...
Keightley AmenTreatment | July 2, 2021
Immune effector cell–associated neurotoxicity syndrome is a clinical and neuropsychiatric syndrome that can occur in the ...
Keightley AmenMultiple Myeloma | July 2, 2021
Targeted immunotherapy is a very promising strategy in the treatment of multiple myeloma (MM). Specifically, clinical trials ...
Keightley AmenMultiple Myeloma | July 2, 2021
Chimeric antigen receptor (CAR) T-cell immunotherapy has shown great promise against hematologic malignancies. Therefore, the ...
Keightley AmenTreatment | July 2, 2021
Chimeric antigen receptor (CAR) T-cell therapy is a rapidly emerging treatment option for patients with B-cell malignancies. ...
Kerri FitzgeraldLymphoma | December 7, 2020
A chimeric antigen receptor (CAR) T-cell therapy induced high response rates in a cohort of patients with indolent ...
Kerri FitzgeraldLymphoma | October 14, 2020
The autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel induced responses in ...
Kerri FitzgeraldLymphoma | August 24, 2020
A study published in the Journal of Clinical Oncology observed that anti-CD30 chimeric antigen receptor (CAR) T-cell therapy ...
Advertisement
Advertisement